United States Eosinophilic Disorders Market Projected to Reach US$ 111 Million by 2031, Growing at a CAGR of 7.1% Driven by Rising Prevalence, Biologics Approvals, and Advancements in Personalized Therapies

Leander, Texas and Tokyo, Japan - Jan.09.2026, As per DataM intelligence research report "The Global Eosinophilic Disorders Market reached US$ 150 million in 2023 and is expected to reach US$ 278 million by 2031, growing at a CAGR of 7.1% during the forecast period 2024-2031." Increasing prevalence of eosinophil-associated conditions, approvals of targeted biologics, and advancements in personalized therapies are driving growth in eosinophilic disorders management.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/eosinophilic-disorders-market?praneetha

☛ United States: Recent Industry Developments
✅ In December 2025, Positive Phase III data for cendakimab highlighted significant histologic and symptomatic improvements in eosinophilic esophagitis (EoE), positioning it as a potential new biologic option for refractory cases.

✅ In November 2025, GSK's depemokimab (ultra long acting biologic) gained expanded indications for severe eosinophilic conditions, offering twice yearly dosing for better patient adherence in asthma and related disorders.

✅ In October 2025, Clinical trials advanced for Siglec-8 inhibitors, showing strong efficacy in hypereosinophilic syndrome (HES) and EoE, with reduced eosinophil activity and improved outcomes.

☛ Japan: Recent Industry Developments
✅ In December 2025, Japanese institutions progressed collaborations on biologic therapies for eosinophilic gastrointestinal disorders, focusing on dupilumab expansions and local patient registries for better outcomes.

✅ In November 2025, Adoption of targeted therapies like benralizumab increased in clinical practice for eosinophilic asthma and EGPA, supported by national guidelines emphasizing precision medicine.

✅ In October 2025, Research advanced on mucosal vaccines and non invasive biomarkers for eosinophilic disorders, enhancing early detection in allergic airway and GI conditions.

☛ Eosinophilic Disorders Market: Drivers
The Eosinophilic Disorders market is expanding due to rising incidence of conditions like eosinophilic esophagitis (EoE), gastritis, and hypereosinophilic syndrome, driven by allergies, environmental factors, and improved diagnostics. Approvals of biologics targeting IL-5, IL-13, and IL-4 pathways (e.g., dupilumab, mepolizumab, benralizumab) offer effective, targeted options reducing reliance on systemic steroids. Increasing awareness, clinical trials, and pediatric indications boost adoption. Advancements in biomarkers and non invasive monitoring support personalized care. High unmet needs in refractory cases and complications like fibrosis drive R&D investments. Overall, these factors are transforming management with safer, disease modifying therapies.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/eosinophilic-disorders-market?praneetha

☛ Eosinophilic Disorders Market: Major Players
Novartis AG, GlaxoSmithKline Plc., Teva Pharmaceutical, Pfizer Inc., AstraZeneca, Sanofi S.A, Curia, LGM Pharma, Henan Lihua Pharmaceuticals Ltd., Hikma Pharmaceuticals, and others.

☛ Segment Covered in the Eosinophilic Disorders Market:
By Type :
Eosinophilic Esophagitis leads the market with 35% share, driven by rising prevalence, increased diagnosis rates, and awareness of esophageal inflammation caused by food or environmental triggers. Eosinophilic Gastritis holds 20% share, supported by growing recognition of stomach related eosinophilic disorders and specialized clinical treatments. Eosinophilic Enteritis accounts for 15% share, driven by advances in small intestine diagnostic techniques. Eosinophilic Colitis captures 12% share, fueled by pediatric and adult cases requiring dietary and medical management. Hypereosinophilic Syndrome represents 18% share, growing due to complex systemic cases requiring targeted pharmacological interventions.

By Treatment :
Medications dominate with 52% share, attributed to the widespread use of corticosteroids, biologics, and immunosuppressive drugs to manage inflammation and control eosinophil levels. Dietary Therapy holds 25% share, supported by elimination diets, elemental formulas, and food allergen management to reduce gastrointestinal symptoms. Dilation procedures capture 12% share, used primarily for severe esophageal narrowing in Eosinophilic Esophagitis. Other treatments, including novel biologics and emerging interventions, represent 11% share, driven by ongoing clinical trials and personalized treatment approaches.

By Distribution Channel :
Hospital Pharmacies lead with 44% share, reflecting the high rate of prescription based therapies and specialized patient monitoring in clinical settings. Retail Pharmacies account for 28% share, supported by availability of maintenance medications and common prescriptions for eosinophilic disorders. Online Pharmacies hold 18% share, growing due to e-commerce adoption, convenience, and home delivery for chronic patients. Other distribution channels, including specialty clinics and direct-to-patient services, represent 10% share, catering to niche treatment needs and telemedicine prescriptions.

☛ Regional Analysis :
North America - 40%
North America leads with 40%, driven by high prevalence of eosinophilic esophagitis and asthma, advanced healthcare infrastructure, strong clinical research, and early adoption of biologics and targeted therapies. The U.S. dominates due to supportive regulatory frameworks and significant investment in novel treatment development.

Europe - 28%
Europe holds 28%, supported by well established healthcare systems, growing awareness of eosinophilic disorders, and increasing adoption of biologics in Germany, the U.K., France, and Italy. Rising clinical trials and reimbursement coverage enhance market growth.

Asia Pacific - 20%
Asia Pacific accounts for 20%, fueled by rising disease awareness, expanding healthcare infrastructure, and increasing adoption of advanced therapies in Japan, China, South Korea, and India. Growth is supported by urbanization and rising patient diagnosis rates.

South America - 6%
South America holds 6%, with Brazil and Argentina as leading markets. Growth is gradual, driven by increasing healthcare awareness and expanding access to specialty therapies for eosinophilic disorders.

Middle East - 4%
The Middle East accounts for 4%, driven by adoption of advanced treatments in UAE, Saudi Arabia, and Israel. Government initiatives to improve healthcare infrastructure and chronic disease management support growth.

Africa - 2%
Africa holds 2%, with limited adoption concentrated in South Africa, Egypt, and Nigeria. Market growth is constrained by low disease awareness, limited access to biologics, and healthcare infrastructure challenges.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=eosinophilic-disorders-market?praneetha

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praneetha
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg?praneetha

Company Name: DataM Intelligence 4Market Research LLP
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.